Clinical Trial

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Study acronym: CARTITUDE-10
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-08-25; most recent amendment 2026-07-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT07149857
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 60 participants
Start Date 2025-10-03
Primary Completion 2028-04-12 (estimated)
Study Completion 2029-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-06